Klinikum Landshut AdoeR Der Stadt Landshut
- Address
- Robert-Koch-Strasse 1, West, 84034 Landshut, Germany
Klinikum Landshut - Comprehensive Cancer and Hematology Research Center
Klinikum Landshut AdoeR der Stadt Landshut operates as a leading clinical research institution with a strong emphasis on oncology and hematology. The center demonstrates particular expertise in gastrointestinal malignancies and blood cancers, conducting multiple Phase III trials that advance treatment paradigms for patients with complex cancer diagnoses.
- Advanced colorectal cancer research including novel pre-operative and post-resection treatment strategies, with focus on stage-guided therapy and ctDNA-guided adjuvant approaches
- Hematologic malignancies including chronic lymphocytic leukemia (CLL) and classical Hodgkin lymphoma, investigating combination immunotherapies and checkpoint inhibition strategies
- Breast cancer research evaluating antibody-drug conjugates in HER2-negative high-risk populations
- Hepatic conditions including liver cirrhosis with portal hypertension, exploring novel combination therapies
The center's research portfolio reflects a commitment to personalized medicine and precision oncology, with particular attention to molecular markers such as circulating tumor DNA (ctDNA), genetic mutations, and risk stratification systems. Through participation in multi-national, multicenter trials, Klinikum Landshut contributes to establishing new treatment standards across diverse therapeutic areas, from surgical oncology to immunotherapy and targeted treatments, ultimately aiming to improve outcomes for patients with both solid tumors and hematologic disorders.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 therapeutic areas and 15 of 22 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 4 by active trials.
- 1AstraZeneca AB2active
lock +3 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB3trials
lock +2 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Klinikum Landshut AdoeR Der Stadt Landshut
lock Showing 1 of 10 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Safety Evaluation of Venetoclax and Obinutuzumab Retreatment in Patients with Recurrent Chronic Lymphocytic Leukemia | AbbVie Deutschland GmbH & Co. KG | Phase II | Recruiting | Mar 2022 | — |
IMP list
lock Showing 1 of 22 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Capecitabine | 4 | Unknown | 2019-12-04 | 2025-04-01 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.